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1. Introduction
Atherosclerosis and vascular disorders, which result from atherosclerosis, represent one of
the major problems in the modern medicine and public health. Atherosclerosis is character‐
ized by structural and functional changes of large arteries. The approaches for the treatment
of atherosclerosis require at least the prevention of growth of atherosclerotic lesions and re‐
duction in the lipid core mass, which would followed by plaque stabilization. Taken togeth‐
er, these approaches could theoretically result in the regression of arterial lesions.
Atherosclerosis develops in the arterial wall and remains asymptomatic until ischemia of distal
organs is evident. Therapy of clinical manifestations of atherosclerosis is largely aimed at
reducing symptoms or affecting hemodynamic response and often does not affect the cause
or course of disease, namely the atherosclerotic lesion itself. Of course, anti-atherosclerotic
effects of statins revealed in many prospective clinical trials may be considered; however,
statins have never been recognized as the drugs indicated just for direct treatment or preven‐
tion of atherosclerosis. They are used predominately in the course of hypolipidemic thera‐
py, and the effects of treatment are estimated by success in reaching the target level of low
density lipoprotein (LDL) cholesterol, but not the regression of atherosclerotic lesion or intima-
media thickness. The last should be considered as beneficial effect, which is mainly due to
pleiotropic mechanisms of action. Atherosclerosis develops over many years, so anti-athero‐
sclerotic therapy should be a long-term or even lifelong therapy. Tachyphylaxis, long-term
toxicity and cost amongst other issues may present problems for the use of conventional
medications in a long-term. Drugs based on natural products can be a good alternative.
© 2013 Orekhov et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In epidemiological studies of hypercholesterolemia, a high level of plasma cholesterol and
the plasma concentration of LDL are significantly associated with the development of pre‐
mature atherosclerosis [1]. Cholesterol accumulation in the arterial wall is the main sign of
atherosclerosis. It was suggested that LDL is the major source of cholesterol deposited in the
vessel wall.
Accumulation of cholesterol and other lipids is the most prominent manifestation of athero‐
sclerosis at the arterial cell level. In addition to lipid accumulation, elevated proliferative ac‐
tivity of vascular cells and enhanced synthesis of the extracellular matrix are characteristics
of cellular atherogenesis. Collagen and glycoproteins are the main components of the extrac‐
ellular matrix which forms a fibrous plaque.
Intracellular lipid accumulation can be induced by LDL; however native lipoprotein does
not increase the cholesterol content of the cell [2]. On the other hand, incubation of cell cul‐
ture with chemically modified LDLs results in a massive accumulation of cholesterol in the
cells [2]. The in vitro studies revealed a great number of atherogenic modifications of LDL,
i.e. modifications which lead to cellular lipidosis [2]. This findings suggest that modified,
but not native LDLs are the source of lipids accumulated in arterial cells. Arterial intimal
cells populating atherosclerotic lesion are overloaded with lipids, their cytoplasm is almost
completely filled with lipid inclusions [3]. These cells are referred to as foam cells.
2. Cellular Mechanisms of Atherosclerosis
Recent studies of the cellular mechanisms of atherosclerosis carried out on cultured human
aortic cells have revealed the outlined below regularities.
Modified LDL circulates in the bloodstream. We have discovered modified (desialylated) LDL
in blood plasma of patients with coronary atherosclerosis [4-7]. This LDL induces accumula‐
tion of cholesterol in arterial cells [4-7]. Naturally occurring modified LDL has lesser sialic
acid, triglyceride and cholesterol contents, lesser particle size, greater density and negative
charge, higher aggregative activity and some other specific features [8]. We have discovered
an enzyme, trans-sialydase, responsible for desialylation of LDL particle in blood [9].
In addition to desialylated LDL, more electronegative LDL and small dense LDL were de‐
tected in human blood [10,11]. We have performed a comparative study of in vivo modified
LDLs. This study showed that more electronegative LDL isolated by ion-exchange chroma‐
tography is desialylated LDL [12]. Desialylated LDL isolated from patient blood [4-7] is
more electronegative LDL. These facts suggest that both desialylated LDL and electronega‐
tive LDL are similar if not identical.
We have found that a particle of desialylated LDL is smaller and denser than that of native
LDL, i.e., this LDL is small dense lipoprotein. On the other hand, La Belle and Krauss
showed that small dense LDL has a low content of sialic acid, i.e., is desialylated [13]. These
findings point out to a similarity between the two types of modified LDL.
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Glycosylation is another type of in vivo LDL modification. Glycosylated LDL was found in
the blood of patients with diabetes mellitus [14]. This LDL is also atherogenic, i.e. induces
intracellular lipid accumulation [15]. Oxidation is probably also one type of an atherogenic
modification of LDL in vivo. There are indirect evidences of the presence of oxidized LDL
in vivo [16].
Autoantibodies are produced in response to the appearance of modified LDL (either desialy‐
lated, glycosylated or oxidized) in the bloodstream [16-18]. Autoantibodies to desialylated
LDL react with both modified and, though with a lesser affinity, native lipoproteins
[17,19,20]. The interaction between anti-LDL autoantibodies and the lipoprotein results in
the formation of LDL-containing immune complexes [12]. Desialylated LDL which enter the
cells as a component of immune complexes possess a higher atherogenic potential compared
with free lipoprotein, i.e. induce a more intense cholesterol accumulation in the cell [21,22].
The interaction with anti-LDL converts native non-atherogenic LDL into atherogenic, i.e. en‐
ables it to induce intracellular cholesterol accumulation which accompanied by enhanced
cell proliferation and the extracellular matrix production [17,20]. We have found circulating
immune complexes consisting of LDL and anti-LDL autoantibodies in the blood of most
atherosclerotic patients [21,22]. A positive correlation between level of LDL-containing im‐
mune complexes and the severity of atherosclerosis has been demonstrated [23-25].
We and others have demonstrated that LDL is able to form complexes with cellular debris,
collagen, elastin, and proteoglycans of human aortic intima [26-28]. Addition of these com‐
plexes to cultured cells stimulated intracellular accumulation of lipids. Experiments with io‐
dinated LDL showed an increased uptake and decreased intracellular degradation of
lipoproteins in complexes.
In 1989 we showed that in vivo and in vitro modified LDLs are spontaneously self-associat‐
ed under cell culture conditions, while native LDLs do not forms self-associates [29]. A posi‐
tive correlation between atherogenic activity of modified LDLs and the degree of LDL self-
association has been established [30,31]. Lipoprotein associates isolated by gel filtration
induced a dramatic increase in the lipid accumulation by cultured human aortic intimal
cells. Removal of LDL associates from the incubation medium by filtration through filter
with pore diameter 0.1 µm completely prevented intracellular lipid accumulation. Thus,
self-association increases atherogenic potential of LDL.
Thus, we can conclude that formation of large complexes (self-associates, immune com‐
plexes, and complexes with connective tissue matrix) by modified LDL leads to intracellular
lipid accumulation through enhanced cellular uptake and slow intracellular degradation of
lipoprotein particles.
3. Anti-Atherogenic and Anti-Atherosclerotic Drugs
Taken together, our data allow us to identify possible targets for anti-atherosclerotic thera‐
py. The first target is atherogenic modification (desialylation) of LDL particle in blood. Pre‐
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vention of LDL modification may be an approach to anti-atherosclerosis therapy. The
second approach may be selective removal of modified LDLs from blood (target 2). The
third one may be based on prevention of modified LDL accumulation in arterial cells (target
3). Also one more approach is removal of excess lipids from foam cells (target 4). Figure 1
schematically represents these four approaches. We have used all of these approaches and
now we believe that the most suitable approach is the third one, namely, the prevention of
modified LDL accumulation in arterial cells. Bellow we describe the application of this ap‐
proach for the development of anti-atherosclerotic therapy.
Agents capable of preventing atherogenesis are anti-atherogenic drugs, agents promoting
the regression of atherosclerotic manifestations are anti-atherosclerotic drugs. Prevention of
intracellular lipid accumulation accompanied by the stimulation of arterial cell proliferation
and massive extracellular matrix production may be regarded as anti-atherogenic (preven‐
tive). In terms of arterial cells, any drug effect which does not prevent directly the conver‐
sion of the normal cell into an atherosclerotic one (foam cell) should be regarded as an
indirect anti-atherogenic action. Only that drug which exhibits its preventive activity at the
arterial level is a direct anti-atherogenic drug. At the arterial cell level, a drug with a direct
anti-atherosclerotic action should induce the regression of the major cellular manifestations
of atherosclerosis, i.e. reduce the intracellular lipid content, suppress cell proliferation and
inhibit the extracellular matrix production.
Figure 1. Targets of anti-atherosclerotic and anti-atherogenic drug actions
Solid circles, multiple modified LDL; open circles, native LDL
(see explanation in the text).
Thus, the drugs that affect atherosclerosis can be divided into 3 groups:
- anti-atherosclerotic;
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- direct anti-atherogenic;
- indirect anti-atherogenic.
4. Cell Model
The identification of anti-atherosclerotic or/and anti-atherogenic activities of a drug is asso‐
ciated with considerable difficulties. There are no simple and rapid techniques to estimate
the anti-atherogenic/anti-atherosclerotic effect of a drug in an animal model or in clinical tri‐
als. That is why we employ a culture of human atherosclerotic vascular cells in the screening
of potential drugs, investigation of their mechanisms of action and optimization of anti-athe‐
rosclerotic drug therapy.
We use human aortic cells to examine the effects of various agents on atherosclerosis-related
features of cultured cells. Cells are isolated from the subendothelial part of the human aortic
intima, i.e. from the part of aorta which is localized between the endothelial lining and the
media [32]. The intima of adult human aorta is a well-defined structure. The thickness of a
normal intima varies from 50 to 120 µm [32]. Sometimes a thickened intima is called a dif‐
fuse intimal thickening [32]. This term underlines its essential difference from a very thin in‐
tima of animal and adolescent aorta. Unaffected intima of adult human aorta contains 10-12
lines of subendothelial cells [32].
Using collagenase and elastase, cells are isolated from the subendothelial layer of the intima
of both normal and atherosclerotic parts of the aorta [33-36]. This approach makes it possible
to study a direct anti-atherosclerotic and anti-atherogenic action of a drug at the vascular
cell level. An important advantage of this technique is that human material is used and thus,
the results obtained are relevant to human atherosclerosis.
By the well-established criteria, the cells cultured from the intima can be classified as the cells
of smooth muscle origin. These cells are stained with antibodies to smooth muscle myosin
[33-35]. For further identification of cultured cells we have used a monoclonal antibody HHF-35
which reacts specifically with muscle α-actin and can reveal smooth muscle cells [37]. Accord‐
ing to our calculations, primary culture of subendothelial cells contains about 90% of smooth
muscle cells interacting with HHF-35. In addition, cells cultured from subendothelial part of
uninvolved (healthy) intima have the ultrastructural features characteristic of smooth mus‐
cle cells, namely: the basal membrane and filament bundles with dense bodies [33-36]. The
culture on which our experiments are performed is represented by mixed population of typical
and modified smooth muscle cells revealed in the human aorta earlier [32].
Cells of the subendothelial intima isolated from atherosclerotic lesions retain in primary cul‐
ture all major characteristics of atherosclerotic cells. Cells cultures from fatty streak and fatty
infiltration zones have an enhanced proliferative activity [38]. These cells have a higher pro‐
liferative activity as compared with the cells cultured from unaffected intima [38,39].
Many cells cultured from atherosclerotic lesions are so called foam cell containing numerous
inclusions filling the whole of the cytoplasm, these inclusions are lipid droplets [34]. The
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bulk of excess lipids in foam cells is represented by free cholesterol and cholesteryl esters
[34]. It should be noted that the content and composition of lipids in cultured cells within
the first 10-12 days in culture remain unchanged and correspond to the respective indices of
freshly isolated cells [34-39].
Cells cultured from the subendothelial intima are capable of synthesizing collagen, proteo‐
glycans and other components of extracellular matrix [40,41].
Thus, the cells isolated from an atherosclerotic lesion of human aorta retain in culture all the
main properties characteristic of atherosclerotic cells. They exhibit an enhanced proliferative
activity, contain excess cholesterol in the form of intracellular inclusions and synthesize the
extracellular matrix. This allows one to regard a culture of atherosclerotic cells as a conven‐
ient model for the investigation of the effects of various agents on atherosclerotic manifesta‐
tions [21]. Thus, the investigations in the cell culture model are carried out directly on
exactly the same cells which require a therapeutic action in vivo.
Using this model, we have examined the effects of different drugs and chemicals. By now
many substances have been tested [21]. The effects of several substances are summarized in
Table 1. Some of them elicited anti-atherosclerotic effects in culture, some proved to be inef‐
fective in this respect, while others even stimulated the development of atherogenic process‐
es.
5. Cardiovascular Drugs
Three classes of cardiovascular drugs: calcium antagonists, beta-blockers and nitrates have
been tested on our cellular model. These drugs are widely used in clinic for therapy of various
disorders resulting from atherosclerosis of different arteries. We attempted to find out how
calcium antagonists, beta-blockers and nitrates affect atherosclerotic indices of arterial cells.
First, we examined the effects of calcium antagonists on major atherosclerotic indices. It has
been found that calcium antagonist, verapamil, has a positive effect on all atherosclerotic
cellular indices. Within 48 hrs, verapamil added to culture reduced total intracellular choles‐
terol level by 3-fold, sharply decreased the [3H]thymidine incorporation into cellular DNA,
i.e. suppressed cell proliferative activity, and inhibited the collagen synthesis by cultured
cells [38,39]. Thus, this drug has a direct anti-atherosclerotic effect at the arterial cell level.
Several calcium antagonists: nifedipine, darodipine, isradipine, nicardipine, nitrendipine, fe‐
lodipine, tiapamil, gallopamil, diltiazem, papaverin, nicardipine, and others were also test‐
ed. Verapamil and nifedipine proved to be the most effective [49,55]. Within 24 hrs of
incubation with cultured cells all calcium antagonists substantially inhibited [3H] thymidine
incorporation and reduced intracellular cholesterol level [54,55]. Thus, calcium antagonists
produce a direct anti-atherosclerotic effect on the vascular cells normalizing the major athe‐
rosclerotic cell parameters.
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Agent References
ANTI-ATHEROSCLEROTIC
Cyclic AMP elevators [39,42 - 45]
Prostacyclin [39,46 - 50]
Prostaglandin E2 [39,46, 51]
Artificial HDL [52]
Antioxidants [39]
Calcium antagonists [39,49, 50, 53-56]
Trapidil and trapidil derivatives [57, 58]
Lipoxygenase inhibitors [51]
Lipostabil [39]
Mushroom extracts [59]
PRO-ATHEROGENIC
Beta-blockers [55,60]
Thromboxane A2 [49,50]
Phenothiazines [39]
INDIFFERENT
Nitrates [55]
Cholestyramine [39]
Table 1. Substances tested on cellular model
In addition to anti-atherosclerotic effects imitating the regression of atherosclerosis, anti-
atherogenic effects in culture imitating prevention of atherosclerosis were studied. Table 2
demonstrates the major differences between these two approaches. In the case of anti-athe‐
rosclerotic effect the regression of atherosclerosis is imitated, whereas in the case of anti-
atherogenic effect, the prevention of atherosclerosis is imitated. In the first case the cells
obtained from an atherosclerotic plaque are used, while in the second type of experiments
cells derived from unaffected intima are employed. When anti-atherosclerotic effect is exam‐
ined, cells are cultured in the presence of a standard fetal calf serum, while in the experi‐
ments on anti-atherogenic effect - atherogenic serum obtained from coronary heart disease
patients is added to culture. This serum induces the accumulation of cholesterol and stimu‐
lates other atherogenic manifestations in cultured cells [61-64]. In the case of anti-athero‐
sclerotic effect the efficacy of a drug is judged upon by its ability to decrease an elevated
content of cholesterol in cultured atherosclerotic cells but in the case of anti-atherogenic ef‐
fect, the efficacy of a drug is judged upon by the ability to prevent the deposition of intracel‐
lular cholesterol in normal cells.
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Four-hour preincubation of cultured cells with verapamil led to complete prevention of the
serum atherogenic effect [65]. Thus, verapamil possesses not only an atherosclerotic effect in
culture causing the regression of atherosclerotic manifestations at the cellular level but also
elicits an anti-atherogenic, i.e. preventive effect, eliminating atherogenic potential of the serum.
ANTI-ATHEROSCLEROTIC ANTI-ATHEROGENIC
Regression Prevention
Atherosclerotic plaque Uninvolved intima
Standard (nonatherogenic) serum Atherogenic patients' serum
Cholesterol fall Prevention of cholesterol accumulation
Table 2. Anti-atherosclerotic and anti-atherogenic drug effects in culture
The effect of several calcium antagonists on primary cholesterol accumulation in cultured
cells induced by the patients' serum was tested. Verapamil and nifedipine completely inhib‐
ited the accumulation of intracellular cholesterol induced by the serum while other calcium
antagonists: diltiazem, nicardipine, isradipine, darodipine rather substantially reduced cho‐
lesterol accumulation [65]. As it is known, the examined calcium antagonists manifested an‐
ti-atherogenic action in vivo inhibiting the development of experimental atherosclerosis in
animals [66,67]. Thus, our in vitro data obtained on cellular model correspond to the in vivo
observations. One can conclude that calcium antagonists elicit not only anti-atherosclerotic
but also anti-atherogenic, i.e. preventive effect at the arterial cell level.
Nitrates and beta-blockers have been tested to reveal their action on atherosclerotic cellular
indices. Nitrates had no effect on proliferative activity of atherosclerotic cells and practically
did not affect the cholesterol level [55]. On the other hand, all the examined beta-blockers,
propranolol, alprenolol, metoprolol, pindolol, and timolol, more or less increased athero‐
sclerotic manifestations, i.e. all of these drugs exhibited atherogenic activity in culture
[55,60]. If beta-blockers manifest a similar action in vivo, one may assume that these drugs
are atherogenic and realize the atherogenic action at the arterial cell level. Apparently, ni‐
trates are neutral, indifferent in this respect.
The influence of cardiovascular drugs on atherosclerosis-related effects of each other was
studied. The study was focused on metoprolol, nifedipine and nitroglycerin, the drugs
widely used in clinic [55]. Metoprolol caused an elevation of intracellular cholesterol, nifedi‐
pine reduced the cholesterol level while nitroglycerin was without effect on this index. The
use of nifedipine on the background of metoprolol did not modify the anti-atherosclerotic
action of the calcium antagonist. In this combination atherogenic action of metoprolol was
not revealed. The application of metoprolol in combination with nitroglycerin led to the
elimination of an atherogenic effect of the beta-blocker. Nifedipine used together with meto‐
prolol and nitroglycerin was just as effective as in the absence of these drugs. Thus, nifedi‐
pine produces its anti-atherosclerotic effects both by itself and in combination with widely
used nitrates and beta-blockers. These data suggest one important conclusion. Atherogenic
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action of beta-blockers can be inhibited if a beta-blocker is used in combination with a calci‐
um antagonist or nitrate. This finding allows to hoping that in the nearest future it will be
possible to develop beta-blockers devoid of atherogenic side effects.
Thus, three classes of cardiovascular drugs reveal different influence on cellular manifesta‐
tion of atherosclerosis. Calcium antagonists exhibit anti-atherosclerotic action. On the con‐
trary, beta-blockers are atherogenic. Nitrates are neutral, indifferent in this respect. Our data
obtained on cellular model were supported by results of clinical study. Loaldi et al. have re‐
ported that long-term per oral administration of propranolol aggravates coronary athero‐
sclerosis in patients with angina of effort as compared with the calcium antagonists,
nifedipiene, and isorobide dinitrate [68]. Nifedipine produced the best effect on coronary
atherosclerosis by suppressing the development of existing and preventing the appearance
of new atherosclerotic lesions. Isosorbide dinitrate was less effective in this respect, while
with propranolol therapy the situation was the worst. These clinical observations encourage
us to develop anti-atherosclerotic therapy using our cell culture model.
6. Ex Vivo Model
All the above conclusions and hypotheses are based on the data obtained in in vitro experi‐
ments. Obviously, the question arises, whether anti-atherosclerotic effects of calcium antago‐
nists and atherogenic effects of beta-blockers can be manifested in vivo and what is the
optimal anti-atherosclerotic therapy based on calcium antagonists and other drugs.
To optimize anti-atherosclerotic and anti-atherogenic drug therapy, ex vivo model was de‐
veloped. In case of ex vivo model not drug but blood serum taken from patients after oral
drug administration is added to cultured cells.
Calcium antagonists, verapamil and nifedipine, and beta-blockers, propranolol and pindo‐
lol, were examined using ex vivo model. Within 2-4 hrs after nifedipine or verapamil admin‐
istration, the patient's serum had anti-atherosclerotic properties, i.e. it was able to cause a
fall in the intracellular cholesterol and inhibited atherosclerotic cell proliferation [55,56]. On
the contrary, the serum of patients who received propranolol or pindolol was pro-athero‐
genic. Its pro-atherogenic properties manifested themselves at the arterial cell level in the
rise of intracellular cholesterol and stimulation of cell proliferation [55,56]. This finding al‐
lows to assuming that not only in vitro, but in vivo as well, calcium antagonists and beta-
blockers are anti-atherosclerotic and atherogenic drugs, respectively.
The effect of nifedipine on serum properties during a prolonged course was assessed. A pa‐
tient was on nifedipine for 7 days. He received 20 mg doses three times a day with an 8-hr
interval. Twenty-eight days after regular nifedipine therapy the initial atherogenicity of the
patient's serum was substantially lower than at the beginning. Directly after a dose of nifedi‐
pine the atherogenicity was practically completely eliminated [65]. On the contrary, as a re‐
sult of a prolonged therapy with a beta-blocker, propranolol, patient's serum acquired stable
atherogenic properties. At the beginning of the course the serum of this patient was nona‐
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therogenic, however, 28 days of regular propranolol therapy led to the emergence of athero‐
genicity revealed even before the drug administration [65]. Thus, a single dose of beta-
blockers brings about temporary atherogenicity of the serum. Prolonged therapy with beta-
blockers leads to the emergence of stable atherogenic properties of patients' blood serum.
7. Optimization of Dietary Therapy
Cellular model can be used not only to test drugs but foodstuffs as well. We have investigat‐
ed an anti-atherosclerotic, i.e. therapeutic, causing regression of atherosclerosis, and anti-
atherogenic, i.e. preventive activity of certain mushroom species and sea products.
Previously we have shown that alcohol and water extracts from 20 Korean mushroom spe‐
cies cause anti-atherosclerotic and anti-atherogenic activity in cell culture [59]. Thirteen of
the 20 extracts tested were anti-atherosclerotic in culture, i.e. they caused a decrease in the
cellular cholesterol and/or inhibited proliferation of atherosclerotic cells. Ten of 20 tested ex‐
tracts displayed anti-atherogenic activity in addition to anti-atherosclerotic effects. Four
mushroom species were chosen for the study of anti-atherosclerotic effects ex vivo. Cultiva‐
tion of atherosclerotic cells during 24 hrs in the presence of serum from healthy subjects who
had had mushroom meals resulted in a 21-30% decrease in the cellular cholesterol level, i.e.
caused anti-atherosclerotic effect [59]. The atherogenic serum obtained from atherosclerotic
patients after dietary mushroom consumption partly (30-41%) lost its ability to increase the
cellular cholesterol content [59]. Thus, tested mushrooms exhibited anti-atherosclerotic and
anti-atherogenic effects on ex vivo model.
Among sea products mollusk and krill meat were tested [36]. Specifically, the patients were
given canned meat of a mollusk belonging to genus Buccinum. Two hours after a single diet‐
ary load the patient's blood serum acquired marked anti-atherosclerotic properties. The ad‐
dition of this serum to cultured atherosclerotic cells led to a fall in intracellular cholesterol
level [36]. Four hours later the anti-atherosclerotic properties of the serum became even
more prominent.
Patients of another group had an initially atherogenic serum causing more then 2-fold in‐
crease in cholesterol content of cells derived from normal intima. These patients received a
single dietary load of Antarctic krill meat. Two hours later the atherogenicity of their blood
serum decreased and four hours later it was practically absent [36]. Thus, krill meat exhibits
a preventive anti-atherogenic action on arterial cells.
The results obtained suggest that the krill meat can be employed in diets aimed at the pre‐
vention of atherosclerosis. To develop a dietary therapy based on the krill meat, the effective
dose and proper regimen should be established. As the first step to develop a dietary thera‐
py, the below outlined study was undertaken to determine the effective dose.
The patients' blood sera were analyzed for atherogenicity. Patients whose blood serum had
an atherogenic potential were included in the study. The blood was collected from each pa‐
tient before, 2 and 4 hrs after a dose of krill meat. This protocol was repeated on the next day
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with another dose of krill meat. Blood serum samples were added to a culture of subendo‐
thelial cells isolated from uninvolved human aortic intima, and intracellular cholesterol ac‐
cumulation was assessed in each case. Anti-atherogenic activity of krill meat was evaluated
by the ability to reduce serum atherogenicity which manifested in cholesterol accumulation
in cultured cells (Figure 2). The dose-effect dependence was revealed by comparing the effi‐
cacy of two doses. The efficacy of each dose was evaluated by the analysis of at least 6 sera
obtained from different patients. In can be seen from that the krill meat elicits an anti-athe‐
rogenic effect at a dose of 10-20 g, half maximum effect was reached at a dose of 30 g and the
maximum effect - at a dose of 50 g.
We believe that this approach will be useful in the development and optimization of anti-
atherosclerotic and anti-atherogenic diet therapies.
Figure 2. Antiatherogenic effect of krill meat on blood serum of atherosclerotic patients
Blood serum atherogenicity was determined using primary culture of cells derived from un‐
involved intima of the human aorta.
8. Natural Products for Anti-Atherosclerotic Therapy
Anti-atherogenic effects of dietary products promote the development of anti-atherosclerotic
therapy on the basis of natural products. Atherosclerosis develops over many years, so the
anti-atherosclerotic therapy should be long-term or even lifelong therapy. For such a long-
term therapy conventional medicine might not work. Drugs based on natural products can
be a good alternative.
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We have tested numerous natural products’ extracts to reveal their effects on blood athero‐
genicity, i.e., a capacity to prevent intracellular cholesterol accumulation caused by athero‐
genic blood sera from patients. Table 3 presents effective natural products only. As a fact,
among tested agents were revealed not only anti-atherogenic but also pro-atherogenic and
neutral. Among antiatherogenic natural products the most effective was garlic.
Atherogenicity
decrease, %
Spirulina platensis 51
Allium cepa 21
Beta vulgaris 31
Triticum vulgaris 70
Glycyrrhiza glabra 55
Salsola collina 11
Allium sativum 77
Pinus sylvestris 52
Table 3. Anti-atherogenic effects of natural products
We extended investigation of the in vitro effect of garlic extract on lipids of cultured hu‐
man aortic cells.  We have earlier shown that lipid accumulation in human aortic cells is
accompanied by stimulation of other cellular manifestation of atherosclerosis, namely: prolif‐
eration and extracellular matrix synthesis [41,63]. Thus, investigation of garlic action on cellular
lipid parameters is closely related to the study of the mechanism of garlic anti-atherosclero‐
sis effect.
A direct influence of garlic on atherosclerosis is discussed [70-73]. The anti-atherosclerotic
effect of garlic has been attributed to its hypolipidemic activity. Experimental and clinical
data have clearly demonstrated that garlic reduces blood cholesterol and LDL levels [74,75].
The cholesterol lowering effect of garlic results from inhibition of hepatic hydroxymethyl‐
glutaryl coenzyme A (HMG-CoA) [76]. In contrast to these studies, we examined not the hy‐
perlipidemic but the direct anti-atherosclerotic-related and anti-atherogenic-related effects
of garlic, i.e., the ability of garlic to act directly on atherosclerotic process in the vessel wall.
To investigate anti-atherosclerotic-related (therapeutic) effect we used smooth muscle cells
cultured from atherosclerotic plaques of human aorta. To study anti-atherogenic-related
(preventive) effect we imitated atherogenesis in primary cultures of smooth muscle cells de‐
rived from grossly uninvolved human aortic intima by adding atherogenic blood serum of
patients with angiographically assessed coronary atherosclerosis. Garlic decreased triglycer‐
ide, cholesteryl ester and free cholesterol contents of cells cultured from atherosclerotic pla‐
que and prevented atherogenic serum-induced accumulation of these lipids in cells cultured
from grossly normal aorta, i.e., elicited direct anti-atherosclerotic-related (therapeutic) and
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anti-atherogenic-related (preventive) effects. Garlic inhibits ACAT and stimulates CEH, thus
displaying a direct influence on synthesis and degradation of cholesteryl esters in the cell.
This finding may explain direct anti-atherosclerotic effects of garlic.
Further investigations of garlic anti-atherosclerotic effects included ex vivo study and ani‐
mal model study. Both types of studies confirmed the in vitro effects of garlic. Finally, we
have developed a drug on the basis of garlic powder and carried out atherosclerosis regres‐
sion clinical study of this drug.
9. Atherosclerosis Regression Clinical Studies of Natural Products
The AMAR study (Atherosclerosis Monitoring and Atherogenicity Reduction) was designed
to estimate the effect of two-year treatment with time-released garlic-based drug Allicor on
the progression of carotid atherosclerosis in asymptomatic men in double-blinded placebo-
controlled randomized clinical trial. The primary outcome was the rate of atherosclerosis
progression, measured by high-resolution B-mode ultrasonography as the increase in caro‐
tid intima-media thickness (IMT) of the far wall of common carotid arteries.
Atherosclerosis affects most vascular beads, and noninvasive imaging of superficial arteries
by ultrasound has been recognized as a surrogate measure of overall atherosclerotic burden
in numerous studies. Extracoronary atherosclerotic lesions can be quickly and safely evalu‐
ated in the carotids, femoral arteries, and the abdominal aorta. The grade of atherosclerosis
in extracoronary sites correlates with a greater number of standard risk factors and, more
importantly, with greater cardiac risk [77]. Of the peripheral arterial surrogates, carotid
atherosclerosis has been most closely correlated with coronary artery disease [78-82]. Pe‐
ripheral arterial ultrasonography is regarded to be a sensitive tool for the detection of early
atherosclerosis and may be useful in assessing response to therapy. Thickening of the inti‐
ma-media of the arterial wall is the earliest detectable anatomic change in the development
and progression of atherosclerosis. High-resolution B-mode ultrasonography is widely used
for noninvasive quantification of carotid IMT as a measure of subclinical atherosclerosis
[83]. Carotid IMT is believed to be a marker of generalized atherosclerosis and is predictive
of clinical cardiovascular events [79,81,84-88]. Thus, ultrasound imaging of intima-media
thickening in carotid arteries served as a means of monitoring atherosclerosis during Allicor
long-term treatment. Indeed, Allicor significantly reduced carotid arterial intima-media
thickness compared to baseline and the placebo group. In Allicor recipients, a significant in‐
crease in the IMT in one or both carotid arteries was observed in 30 (32.2%) patients, and
was significantly reduced in 44 (47.3%) patients. In 8 patients (8.6%) there were no signifi‐
cant IMT changes in either the carotid artery, and in the remaining 11 patients (11.8%) diver‐
gent changes were observed, i.e. IMT increased in one carotid artery and decreased in the
other. IMT lesion progression was observed in 50 (48.5%) placebo cases, and decreased sig‐
nificantly in one or both arteries in 31 (30.1%) patients. Stable situation was observed in 11
(10.7%), and divergent changes occurred in the remaining 7 (6.8%) patients. The difference
in the IMT changes between Allicor and placebo recipients was statistically significant (Pear‐
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son’s chi-square 9.788, P=0.020). Thus, while spontaneous atherosclerosis progression pre‐
vailed in the placebo group, Allicor beneficially impacted early carotid atherosclerosis -
significantly increasing lesion regressions and reducing the net number of progressive
lesions (Figure 3). The trend to IMT reduction in Allicor recipients was observed already af‐
ter first 3 months of the study, and became statistically significant different from the base‐
line measures as well as from placebo group after the first 12 months of treatment. At the
end of the two-year study the difference between placebo and Allicor recipients increased
and remained statistically significant. The overall lesion progression was clearly different in
the treated and untreated groups. IMT in the common carotid artery rose 0.015±0.008 mm
annually and above a mean baseline IMT of 0.931±0.009 mm in the placebo group, and fell in
Allicor-treated patients at a rate of -0.022±0.007 mm per year (P=0.002). Though the benefit
of Allicor was more pronounced in year 1 (-0.028±0.008 mm) it remained significant and as a
statistically identical significant difference in year 2 (-0.016±0.007).
Figure 3. The dynamics of IMT changesSolid circles, Allicor-treated patients; open circles, placebo patients. *, signifi‐
cant IMT change as compared to baseline, P<0.05;#, significant difference from placebo group, P<0.05.
The beneficial effects of Allicor were also revealed in analysis of subgroups of patients who
had significant increase or reduction in IMT. IMT progression was almost 2.5 fold higher in
the 50 patients in the placebo group with progress (0.070±0.016 mm) than in Allicor-treated
patients with atherosclerosis progression (n=30, 0.029±0.011 mm increase, P=0.038). Similar‐
ly, spontaneous atherosclerosis regression in placebo recipients (n=31) was half as promi‐
nent (-0.041±0.014 mm) than in Allicor-treated patients (n=44, -0.082±0.015 mm, P=0.049).
The results obtained in our study are generally in good coincidence with the data from re‐
cent double-blinded placebo-controlled randomized study by Koscielny et al. [89]. It has
been demonstrated that 4-year treatment with garlic-based drug Kwai inhibited the increase
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in the volume of atherosclerotic plaques in carotid and femoral arteries by 5-18%. The age-
dependent representation of the plaque volume has shown an increase between 50 and 80
years that was diminished under garlic treatment by 6-13% related to 4 years. So, with garlic
application the plaque volume in the whole collective remained practically constant within
the age-span of 50-80 years [89].
Overall, the regression of subclinical atherosclerosis was much more frequently observed in
asymptomatic men who randomly received Allicor than in those who received placebo. A
rather high proportion of patients in placebo group who demonstrated spontaneous regres‐
sion, especially at early stages of atherosclerosis, reflects an interesting but poorly under‐
stood aspect of vascular biology that requires further study. The decrease in IMT achieved
during the AMAR study is quite comparable with the results of most successful trials with
other compounds (Table 4). Although, these studies employed potent lipid-lowering agents
either calcium antagonists whose beneficial effects of treatment were attributed to reduc‐
tion in LDL cholesterol,  the major risk factor for atherosclerosis development, or arterial
wall stress.
Trial Medication Mean annual IMT change, mm Reference
placebo treatment
PLAC II Pravastatin 0.068 0.059 [91]
KAPS Pravastatin 0.029 0.010 [90]
ASAP Simvastatin - -0.009 [92]
PREVENT Amlodipine 0.011 -0.015 [93]
ASAP Atorvastatin - -0.020 [92]
CLAS Cholestipol, niacin 0.010 -0.020 [94, 95]
MARS Lovastatin 0.015 -0.028 [94, 96]
VHAS Verapamil - -0.028 [97]
AMAR Allicor 0.015 -0.022 This study
Table 4. The comparative data from clinical trials on carotid atherosclerosis regression
The main scientific goal of the given double-blinded, placebo-controlled randomized study
was to test the hypothesis that long-term lowering of serum atherogenicity may prevent the
initial stage of atherogenesis, namely, the excessive deposition of cholesterol in the cells of
the arterial wall, thus inhibiting further formation of atherosclerosis lesion [41,62].
At the baseline, the sera from 17 patients in placebo group (16.5%) did not induce significant
cholesterol accumulation in cultured cells, while the sera from other 86 patients were athero‐
genic, i.e. induced a statistically significant (1.2- to 3.9-fold) increase in intracellular choles‐
terol content (mean result, 166.3±5.5, % of control value). In Allicor-treated patients, 23
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patients (24.7%) had non-atherogenic sera, and in other 70 patients the sera increased intra‐
cellular cholesterol by 1.2- to 3.5-fold (mean result, 172.1±5.8, % of control value).
Among patients with non-atherogenic sera at the baseline, in placebo recipients blood serum
atherogenicity arrived in 11 cases during the study; in Allicor-treated patients at the end of
the study serum atherogenicity was revealed in 9 cases, and in other 14 patients the sera re‐
mained non-atherogenic. The difference between Allicor and placebo recipients was statisti‐
cally significant (Pearson’s chi-square 11.023, P<0.001). Thus, Allicor treatment prevented
the upraise of blood serum atherogenicity.
Among patients with initially atherogenic sera, in placebo group blood serum atherogenici‐
ty spontaneously decreased in 26 patients, did not change significantly in 28 patients, and in
32 cases there was further increase in blood serum atherogenic potential. On the opposite, in
Allicor group serum atherogenicity was decreased in 39 patients by the end of the study, re‐
mained unchanged in 18 patients, and further increase in serum ability to induce intracellu‐
lar cholesterol accumulation was observed only in 13 cases. Again, the difference between
Allicor and placebo recipients was statistically significant (Pearson’s chi-square 11.274,
P=0.004). Thus, Allicor also induced a fall in blood serum atherogenicity, if it existed at the
beginning of treatment.
Figure 4. The dynamics of serum atherogenicity changesSolid circles, Allicor-treated patients; open circles, placebo pa‐
tients. *, significant IMT change as compared to baseline, P<0.05;#, significant difference from placebo group, P<0.05.
The overall dynamic of changes in serum atherogenicity is presented in Figure 4. At the
baseline, serum taken from patients was able to induce 1.56-fold increase in intracellular
cholesterol content in cell culture test. In the placebo group, the mean level of serum athero‐
genic potential did not change significantly during two years of the study. On the opposite,
in Allicor-treated patients the mean value for the ability of serum to induce intracellular lip‐
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id accumulation was significantly lowered (P=0.016) approximately by 30% of the initial lev‐
el (95% CI: 16.9, 41.0) already after first 3 months of study, and this effect was maintained
during the study. General linear model analysis has demonstrated the statistically signifi‐
cant difference in the dynamic of changes in serum atherogenicity between Allicor-treated
and placebo groups (P=0.008).
The presence or absence of serum atherogenicity at the baseline, as well as the extent of se‐
rum-induced intracellular cholesterol accumulation at the baseline, did not correlate with
the following changes in IMT. However, the statistically significant correlation has been re‐
vealed between the changes in blood serum atherogenicity during the study and the
changes in intima-media thickness of common carotid arteries (r=0.144, P=0.045 for the total
study sample). In patients with initially non-atherogenic sera, the correlation between
changes in atherogenicity and IMT was stronger (r=0.342, P=0.031). This correlation is ex‐
plained mainly by the arrival of serum atherogenicity during follow-up in a subgroup of
placebo recipients with initially non-atherogenic sera; in them the correlation between in‐
crease of atherogenicity and IMT dynamics was the highest (r=0.517, P=0.034).. In patients
with initially atherogenic sera, the correlation between changes in atherogenicity and IMT in
total group did not reach statistical significance (r=0.147, P=0.067), but in Allicor-treated pa‐
tients in most of whom the decrease in serum atherogenicity was observed, the above pa‐
rameters correlated well (r=0.254, P=0.034).
There is a substantial experimental background to explain the possible mechanisms under‐
lying a direct anti-atherosclerotic action of Allicor. The components of garlic can regulate
two main intracellular enzymes responsible for cholesterol intracellular metabolism. Garlic
extract stimulates cholesteryl ester hydrolase and inhibits acetyl coenzyme A : cholesterol
acyl transferase, thus diminishing intracellular content of cholesteryl esters [98]. Additional‐
ly, garlic extract inhibits cellular proliferative activity and the synthesis of connective tissue
matrix components [98,99]. Allicor also possesses antioxidant activity and lowers LDL sus‐
ceptibility to oxidation [99]. Allicor prevents serum-induced cholesterol accumulation in
cells cultured in the presence of patient’s serum taken after single dose of Allicor adminis‐
tration; in other words, it reduces serum atherogenic potential [99]. In animal studies, garlic-
based preparations inhibit the formation of neointimal thickening in cholesterol-fed rabbits
[100]. So, it could be easily proposed that long-term Allicor treatment produced a direct anti‐
atherosclerotic effect due to the prevention of lipid deposition and depletion of cholesterol
pool already accumulated in arterial wall.
Garlic contains a variety of organosulfur compounds, amino acids, vitamins and minerals
[101]. Some of the sulfur-containing compounds such as allicin, ajoene, S-allylcysteine, S-
methylcysteine, diallyl disulfide and sulfoxides may be responsible for antiatherosclerotic
activity of garlic [98,100]. Many garlic-based products are present on the market now. As
compared to other garlic preparations, dehydrated garlic powder is thought to retain the
same ingredients as raw garlic, both water-soluble and organic-soluble, although the pro‐
portions and amounts of various constituents may differ significantly [102,103]. Allicor con‐
tains just garlic powder; on the other hand, it possesses a prolonged mode of action, as its
antiatherogenic effect lasts for 12-16 hours after single dose administration [99]. So, Allicor
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differs greatly from other garlic-based preparations and may have considerable benefits in
medicinal use.
On the whole, the results of our study demonstrate that long-term treatment with time-re‐
leased garlic-based drug Allicor provides a direct anti-atherosclerotic effect on carotid athe‐
rosclerosis. Being the remedy of natural origin, Allicor is safe with the respect to adverse
effects and allows even perpetual administration, which may be quite necessary for preven‐
tion and treatment of subclinical atherosclerosis. These results encouraged clinical trials of
two other drugs based on natural products, including: Inflaminat, possessing anti-cytokine
activity and the phytoestrogen-rich drug Karinat, designed for postmenopausal women.
Atherosclerosis is regarded as a pathological process with elements of local aseptic inflam‐
mation, while inflammatory cytokines play a role at every stage of atherosclerosis develop‐
ment [104-107]. In this regard, drugs with systemic anti-inflammatory action may be
effective for the prevention of atherosclerosis. In our study, we investigated the atheroscle‐
rosis regression effect of natural drug Inflaminat based on calendula, elder and violet. These
plants are widely used in herbal medicine as anti-inflammatory agents. In a pilot study of
Inflaminat using a protocol similar to the AMAR study Inflaminat demonstrated atheroscle‐
rosis regression effects and statistically significant difference from the baseline as well as
from placebo group (Table 5). Thus, Inflaminat possesses atherosclerosis regression effect in
asymptomatic men.
Inflaminat Placebo р**
Number of participants 81 77 -
IMT, μm
-62±48 *
(-91; -32)
р=0,002
42±75
(-9; 93)
р=0,109
0.002
Table 5. Carotid IMT changes in 1-year Inflaminat pilot study* significant differences, p<0.05, Wilcoxon's signed
ranked test;**statistical significance of differences was estimated by Mann-Whitney U-test.
Atherosclerosis prevention in postmenopausal women is a striking problem, since modern
medicine does not provide any effective approach. Hormone replacement therapy was re‐
jected as a tool for atherosclerosis prevention in women due to the negative results of recent
studies – WHI, PEPI and HERS [108-113]. So, the development of novel approaches is highly
demanded. Phytoestrogens are often regarded as a possible alternative to hormone replace‐
ment therapy, but practically nothing is known on their effects on atherosclerosis.
We screened many natural phytoestrogen-rich components for their antiatherogenic activity
using an ex vivo test system [39,61,114-117]. The most promising of these compounds were:
garlic powder, extract of grape seeds, green tea leafs and hop cones - all produced a signifi‐
cant antiatherogenic effect. On the basis of their combination, the novel isoflavonoid-rich di‐
etary supplement Karinat was developed. It produces the most efficient antiatherogenic
effect in cell culture models and is characterized by improved phytoestrogen profile, provid‐
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ing additional amounts of biologically active polyphenols including resveratrol, genisteine
and daidzeine that are claimed to produce some effects on atherosclerosis development.
Karinat also contains additional amounts of β-carotene, α-tocopherol and ascorbic acid to
provide the necessary daily intake of antioxidants
A randomized double-blinded placebo-controlled pilot clinical study on atherosclerotic ef‐
fect of Karinat was performed in healthy peri- and postmenopausal women to understand
the risks and benefits of phytoestrogen therapy in relation to atherosclerosis progression.
The primary endpoint was the annual rate of changes in common carotid artery intima-me‐
dia thickening, and the secondary endpoint was the dynamics of climacteric syndrome, that
is monitored only in perimenopausal women. Table 6 demonstrates the effect of Karinat
treatment on the dynamics of carotid atherosclerosis in postmenopausal women. In the pla‐
cebo group an increase in the average IMT of more than 100 µm per year was observed.
Thus, the rate of the natural history of atherosclerosis in postmenopausal women is extreme‐
ly high: the average increase in IMT is 13% per year, and growth of atherosclerotic plaques
of 40% per year.
Karinat Р Placebo Р
Number of participants 80 - 77 -
IMT, μm +6 (85) p<0.05 +111 (91) p<0.02
Plaques, scores +0,21 (0,59) 0,009 +0,31 (0,55) <0,001
Table 6. Carotid IMT changes in 1-year Karinat pilot study on postmenopausal women
In the Karinat group a completely different picture was observed. The average IMT of caro‐
tid arteries was not changed (statistically insignificant increase of 6 µm per year, i.e. less
than 1%). However, the progression of existing plaques by 27% per year was detected.
The results of quantitative measurements of the degree of atherosclerosis in the dynamics
have shown that the use of phytoestrogen complex in postmenopausal women almost com‐
pletely suppresses the formation of new atherosclerotic lesions and 1.5-fold slows the pro‐
gression of existing lesions.
Thus, as in the AMAR trial Inflaminat caused regression of carotid atherosclerosis while
Karinat prevented its development. It should be noted that the anti-atherosclerotic effects of
drugs based on natural products are not inferior to the effects of such drugs as statins and
calcium antagonists (Table 4). Thus, natural products can be considered as promising drugs
for anti-atherosclerotic therapy.
10. Conclusion
This review illustrates the use of cultured human arterial cells for:
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- mass screening of drugs and chemicals (cyclic AMP elevators, calcium antagonists, prosta‐
glandins, - blockers, antioxidants, etc.);
- investigation of the mechanisms responsible for the atherosclerosis-related effects (calcium
antagonists and lovastatin);
- optimization of anti-atherosclerotic and anti-atherogenic drug and dietary therapy (β-
blockers, calcium antagonists, mushrooms, krill meat).
Cell cultures enable one to perform investigation on models: - in vitro (mass screening,
study of the mechanism of drug action);
- ex vivo (study of the mechanism of drug action, optimization of therapy);
- in vivo models (animals with experimental atherosclerosis) allowed us to confirm the re‐
sults obtained on in vitro and ex vivo models.
The in vitro and ex vivo models can be employed to reveal and investigate of:
- direct anti-atherosclerotic activity - regression of atherosclerosis (calcium antagonists, pros‐
taglandins, antioxidants, lipostabil, mushrooms, mollusk meat, etc.);
- direct anti-atherogenic activity - prevention of atherosclerosis (calcium antagonists, mush‐
rooms, krill meat);
- indirect anti-atherogenic activity (lovastatin);
- atherogenic activity (β-blockers, thromboxane, phenothiazines).
Natural products can be considered as promising drugs for anti-atherosclerotic therapy.
Two-year treatment with Allicor (garlic powder) has a direct anti-atherosclerotic effect on
carotid atherosclerosis in asymptomatic men. Inflaminat (calendula, elder and violet), pos‐
sessing anti-cytokine activity, caused regression of carotid atherosclerosis as a result of 1-
year treatment of asymptomatic men. Phytoestrogen-rich drug Karinat (garlic powder,
extract of grape seeds, green tea leafs, hop cones, β-carotene, α-tocopherol and ascorbic
acid) prevented development of carotid atherosclerosis in postmenopausal women.
Our basic studies have shown that cellular lipidosis is the principal event in genesis of athe‐
rosclerotic lesion. Using cellular models and natural products we have developed an ap‐
proach to prevent lipid accumulation in arterial cells. This led to regression of
atherosclerosis and/or prevention of its progression in patients. So, our basic findings were
successfully translated into clinical practice. As a result of this translation novel approach to
anti-atherosclerotic therapy was developed. On the basis of our knowledge we developed
drugs possessing direct anti-atherosclerotic activity. Our clinical trial confirmed the efficacy
both novel approach and novel drugs.
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